SpyGlass Pharma Inc
Research SpyGlass Pharma Inc (SGP) on Bullrun: market cap USD 833.48M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSGP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 833.48M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 19.86M
- Free cash flow-USD 16.77M
Valuation Snapshot
latest market cap is USD 833.48M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 39.87M | -USD 33.49M | n/a | -17.98 | USD 96.36M | USD 1.58M | -USD 98.84M |
| FY2024 | USD 0 | -USD 29.16M | -USD 24.02M | n/a | -16.31 | USD 16.27M | USD 3.90M | -USD 60.47M |
| FY2023 | USD 0 | -USD 13.32M | -USD 12.49M | n/a | -1.17 | USD 15.85M | USD 0 | -USD 32.99M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 833.48M | n/a | n/a | n/a |
About SpyGlass Pharma Inc
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SpyGlass Pharma Inc's market cap?
SpyGlass Pharma Inc's market capitalization is USD 833.48M.
What does SpyGlass Pharma Inc do?
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc.